

Non-hospitalised, vaccinated adults with COVID-19 caused by Omicron BA.1 and BA.2 present with changing symptom profiles compared to those with Delta despite similar viral kinetics

Hermaleigh Townsley^{1,2*}, Edward J Carr^{1*}, Timothy W Russell^{3*}, Lorin Adams⁴, Harriet V Mears¹, Chris Bailey¹, James RM Black⁵, Ashley S Fowler¹, Katalin Wilkinson¹, Matthew Hutchinson¹, Ruth Harvey⁴, Bobbi Clayton¹, Gavin Kelly¹, Rupert Beale^{1,5}, Padmasayee Papineni⁶, Tumena Corrah⁶, Simon Caidan¹, Jerome Nicod¹, Steve Gamblin¹, George Kassiotis^{1,7}, Vincenzo Libri^{2,4}, Bryan Williams^{2,4}, Sonia Gandhi^{1,5}, Adam J Kucharski³, Charles Swanton^{1,5}, Emma C Wall^{*1,2}, David LV Bauer^{* 1,8}

Affiliations

1. The Francis Crick Institute, 1 Midland Road, London, UK
2. National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK
3. Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK
4. Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London, UK
5. University College London, Gower Street, London
6. London Northwest University Healthcare NHS Trust, London
7. Department of Infectious Disease, St Mary's Hospital, Imperial College London, London
8. Genotype-to-Phenotype UK National Virology Consortium (G2P-UK)

*These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Senior authors:

Sonia Gandhi, Adam J Kucharski, Charles Swanton, Emma C Wall, David LV Bauer

Correspondence to:

David LV Bauer (david.bauer@crick.ac.uk) and Emma Wall (emma.wall@crick.ac.uk)

Running title:

Symptom and viral load in breakthrough infections with Delta or Omicron BA.1 & BA.2

Keywords

COVID-19, Symptoms, Variant of concern, Delta, Omicron, Viral Load

40 word summary

We provide prospective characterisation of COVID-19 caused by Delta and Omicron BA.1 and BA.2 in healthy, vaccinated adults. A minority of adults report symptoms that would mandate self-isolation, despite having equally high viral shedding across VOCs that persisted beyond ten days.

Abstract

Introduction

The impact of COVID-19 vaccination on disease in the community has been limited, as a result of both SARS-CoV-2 Variants of Concern that partially escape vaccine-induced immunity. We sought to characterise symptoms and viral loads over the course of COVID-19 infection in otherwise-healthy vaccinated adults, representative of the general population, to assess whether current self-isolation guidance remains justified.

Methods

In a prospective, observational cohort study, healthy vaccinated UK adults who reported a positive PCR or lateral flow test, self-swabbed on alternate days until day 10. We compared symptoms and viral kinetics between infections caused by VOCs Delta and Omicron (sub-variants BA.1 and BA.2) and investigated applicability of UK NHS isolation guidelines to these newer VOCs.

Results

373 infection episodes were reported among 349 participants. Across VOCs, symptom duration was similar, however symptom profiles differed significantly among infections caused by Delta, Omicron BA.1 and BA.2. Anosmia was reported in <10% of participants with BA.1 and BA.2, compared to 42% with Delta infection, coryza fatigue and myalgia predominated. Most notably, viral load trajectories and peaks did not differ between Delta, BA.1 and BA.2, irrespective of symptom severity, VOC or vaccination status.

Conclusion

COVID-19 isolation guidance should not differ based on symptom severity or febrile illness and must remain under review as new SARS-CoV-2 VOCs emerge and population immunity changes. Our study emphasises the ongoing transmission risk of Omicron sub-variants in vaccinated adults with mild symptoms that may extend beyond current isolation periods.

Introduction

COVID-19 causes a wide range of symptoms in humans; recognition of this diversity now forms the core of global public health messaging, including in the United States, where the Centers for Disease Control and Prevention (CDC) recognise a set of eleven possible symptoms (CDC, 2022)(1). The emergence of new viral variants of concern (VOCs) with substantially different properties such as innate immune antagonism(2) and tissue tropism,(3) has occurred despite widespread vaccination inducing durable immune responses to these variants (4-6). While vaccination has led to widespread population immunity and dramatic reductions in hospitalisation and deaths in the UK, infection and transmission are less affected by vaccination (7, 8). High numbers of COVID-19 cases caused by the Omicron BA.1 and BA.2 VOCs in vaccinated individuals were reported across UK surveillance systems between December-May 2022 (9).

Early reports of Omicron BA.1 infection from South Africa in December 2021 suggested this VOC caused a less-severe clinical disease, as measured by crude outcomes of hospitalisation and mortality rates; in the context of highly vaccinated European populations, similar trends have been reported (7, 8, 10). While these are encouraging data, they do not account for the significant impact of community COVID-19 infections in non-hospitalised adults, with attendant risks of onward transmission, burden on healthcare, particularly post-COVID syndrome (PCS)(11, 12). Few studies have prospectively examined relationships between symptoms and VOC infection in non-hospitalised adults, reporting substantial changes in symptoms of COVID-19 between VOCs, but have either not captured asymptomatic infections or controlled for time since last vaccine dose (13, 14).

The NHS's COVID-19 guidance was changed in April 2022, expanding the list of cardinal symptoms, advised self-isolation based on the presence of fever or illness severity and defined recommended isolation periods (5 days for general contact, 10 days for large crowds

or contact with clinically-vulnerable individuals) (15). The guidance also removed the explicit/general recommendation for the use of non-pharmaceutical interventions (NPIs) and testing following COVID symptoms in parallel with withdrawal of mass COVID-19 testing in the United Kingdom on 1 April 2022. Reduced access to free testing places an increased burden of responsibility on individuals to self-diagnose SARS-CoV-2 infection and take action to prevent infection of contacts. To investigate if the current symptom-based guidance to self-isolate is appropriate for Omicron BA.1 and BA.2, we compared symptom burden and viral kinetics between healthy, vaccinated adults infected with SARS-CoV-2 variants Delta, BA.1 and BA.2, stratifying the cohorts by vaccine doses and time since last dose.

Methods

Clinical cohort

We carried out a fourth analysis of the Legacy study cohort (NCT04750356) to assess symptoms and viral load in infections caused by Delta and both Omicron BA.1 and BA.2 following two- or three-dose vaccination. We locked the dataset for this analysis on 16 May 2022 and censored any infection episodes 14 days prior, to mitigate against recent missing symptom diaries. The Legacy study was established in January 2021 by University College London Hospitals and the Francis Crick Institute to track serological responses to vaccination during the national COVID-19 vaccination programme in healthy staff volunteers. All participants at the time of commencement were undergoing weekly or biweekly occupational health testing for COVID-19. Participants were recruited prospectively, following either a dose of COVID-19 vaccination or a positive COVID test. All participants reporting infection either detected through asymptomatic PCR screening or symptomatic testing had same-day swabs collected by courier on alternate days up to day 10 post symptom onset, with an additional swab where possible between day 11 and day 30. Symptom severity in non-hospitalised adults was self-reported, symptom diaries were cross-checked with a study clinician at a post-infection study visit within 30 days of the first positive test. To capture the scale of symptom

severity experienced by participants, we assigned symptom severity categories to those with asymptomatic infection (0), mild (I), moderate (II) and severe (III), expanding the WHO categories 1-2 (16), in the absence of validated severity scores for non-hospitalised adults. Symptoms were defined as follows, grade I: “does not interfere with the participant's daily routine and does not require further procedure; it causes slight discomfort”; grade II: “interferes with some aspects of the participant's routine, or requires further procedure, but is not damaging to health; it causes moderate discomfort”; grade III: “results in alteration, discomfort or disability which is clearly damaging to health”. We further categorised symptom profiles in two ways, excluding individuals who had not completed a symptom diary. Firstly, into three categories based on the original NHS symptoms of COVID-19: symptomatic with one or more “classic” cardinal NHS symptoms (cough, fever, anosmia), symptomatic with only non-cardinal symptoms, or not symptomatic. Secondly, into four categories using the updated NHS guidance(17) on the triggers for isolation with symptomatic SARS-CoV-2: asymptomatic, symptomatic and afebrile, febrile alone, and febrile with other symptoms.

SARS-CoV-2 RT-qPCR and sequencing

RNA was extracted from nasopharyngeal swabs taken at time of breakthrough infection, as previously described.(18) Viral RNA was genotyped by RT-qPCR (TaqPath COVID-19 CE-IVD Kit, ThermoFisher) to confirm SARS-CoV-2 infection. Viral RNA from positive swabs was prepared for whole-genome sequencing using the ARTIC method (<https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye>) and sequenced on the ONT GridION platform to >30k reads / sample. The data were demultiplexed and processed using the viralrecon pipeline (<https://github.com/nf-core/viralrecon>).

Data analysis, statistics, and availability

Study data were collected and managed using REDCap electronic data capture tools hosted at University College London. Data were exported from REDCap into R for visualisation and

analysis.(19) For this analysis, data were exported on 16th May 2022. Summary descriptions of the clinical cohort and of reported symptoms and measured viral loads were generated, specifying calculation of median and IQR for continuous variables. We excluded infection episodes from analyses if their infection was ≤ 14 days after a vaccination, or if < 14 days had passed between the infection date and date of data export. For each infection episode, whole genome sequencing or a combination of date of infection and viral genotype was used to assign the VOC that caused the infection. Infection episodes were grouped by VOC and participant's number of vaccinations and days since last vaccine dose. For the duration of symptoms and time-since-dose comparisons, infection episodes were grouped as above, and an unpaired two-tailed Wilcoxon test performed.

SARS-CoV-2 PCR data were analysed using the Cycle Threshold (Ct) of the ORF1ab gene target; smoothed spline fits were applied to Ct trajectories of all participants for each VOC. A correction of -1d was applied to surveillance tests, assuming most tests were taken on the preceding evening, and a linear model was used to correct for the differences in Ct between a dry viral swab and a swab in viral transport medium. Peak Ct values were drawn from the lowest Ct value (corresponding to the highest viral load) obtained from each participant between days 1-4. Ct values were compared using an unpaired two tailed Wilcoxon test.

Graphs were generated using the *ggplot2* package in R. All data (anonymised) and full R code to produce figures and statistical analysis presented in this manuscript are freely available online on Github: <https://github.com/davidlvb/Crick-UCLH-Legacy-Symptoms-2022-03>

Ethical approvals

The Legacy study was approved by London Camden and Kings Cross Health Research Authority Research and Ethics committee (IRAS number 286469) and is sponsored by University College London Hospitals.

Results

Infection following vaccination was reported in 373 episodes across 349 participants. We were able to confidently determine the VOC that caused the infection in 335/373 (90%) of episodes using a combination of methods: by infection date relative to the dominant circulating VOC (273/335, 81%), a combination of infection date and viral genotyping for those during periods without a single dominant circulating variant in (205/335, 61%), confirmed by viral genome sequencing (162/335, 48%) (**Figure 1**). We were unable to resolve the VOC in 38/373 episodes (10%) due to inconsistencies in genomic data and overlapping periods of VOC dominance; these episodes were excluded from analysis. Cases within 14 days of vaccination did not meet the definition of post-vaccine infection and were excluded (26/335, 8%), as were 2 Alpha infections (one determined by date; one by SGTF and date). The remaining 307 episodes, across 292 individuals, were then analysed (**Table 1**). These individuals had the same age distribution (median 39 years [IQR 31-48], as the whole Legacy study (39 years [31-49])), and were gender matched to Legacy (67 vs 66% female). Symptom questionnaires were completed for 297/307 episodes (97%). We then stratified cases into five cohorts according to the dominant combinations of participant vaccination status and virus variant (**Figure 2A**): Delta infection following 2 doses (2d+Delta: n=61, occurring a median of 156 [IQR 110-190] days since last vaccine), Delta following 3 doses (3d+Delta: n=6, 36 [25-56] days), Omicron BA.1 following 2 doses (2d+BA.1: n=20, 212 [170-261] days), Omicron BA.1 following 3 doses (3d+BA.1: n=116, 78 [44-100] days, and Omicron BA.2 following 3 doses (3d+BA.2: n=104, 109 [92-157] days).

While asymptomatic infections were reported in each cohort, ranging from 5/5 (100%) in 3d+Delta to 13/99 (13%) in 3d+BA.2 Omicron, the majority of participants (226/297, 76%) reported grade I-II severity illness. We found the proportion of BA.1 and BA.2 participants with asymptomatic infection was significantly lower (BA.1 28% asymptomatic [32/144], BA.2 13% asymptomatic [13/99]; χ^2 test p=0.046) (**Figure 2B**). In the symptomatic cohort, the median

duration of infection was 9 [IQR 7-14] days (**Figure 2C**). The median illness duration overall did not differ significantly among any of the groups.

There were significant changes in the specific profile of symptoms between cohorts (**Figure 2D**), with anosmia specifically reported in significantly fewer cases in the Omicron cohorts (7-20%) as compared to d2+Delta (41%, $P=7.43 \times 10^{-6}$ or 2.3×10^{-7} ; χ^2 test d2+Delta vs. Omicron BA.1 or vs. BA.2, respectively). While cough was reported slightly more frequently in d2+Omicron BA.1 as compared to d2+Delta, this difference was not significant (45% vs. 39%, $P=0.85$). Indeed, despite reports of changes in tissue tropism in laboratory studies of Omicron BA.1,(3) the proportion of participants reporting coryza, fatigue, myalgia, fever, shortness of breath, and diarrhoea remained broadly similar across all combinations of cohorts that reported symptomatic illness (d2+Delta, d2+BA.1, d3+BA.1 and d3+BA.2).

Notably, in triply vaccinated individuals who experienced Omicron BA.1 infection, only half reported one or more symptom of the NHS's classical triad of COVID-19 (**Figure 2E**), with ~20% asymptomatic and another ~30% experiencing only non-classical symptoms; a slightly higher proportion reported cardinal symptoms following BA.2 infection, dominated by cough (55%). Using the UK NHS's updated self-isolation guidance accessed 24th June 2022,(15) we estimated the proportion of infections with either BA.1 or BA.2 that would trigger self-isolation due to the presence of fever is 23% or 37%, respectively, in vaccinated adults after a third dose (**Figure 2F**).

We undertook a hierarchical clustering analysis of the symptom data to investigate which symptoms presented simultaneously (**Figure 3**). While both coryza and fatigue clustered together in the majority of cases (55-73%, 45-67% respectively), cough (39-55%) and fever (20-36%) were less likely to be reported together; myalgia was reported in a minority of cases (around one-third), and clustered with fatigue (**Figure 3A**). Symptoms caused by infections with Omicron BA.1 and BA.2 were dominated by clusters consisting of cough, coryza and

fatigue; fever and myalgia were less common, but did predominately occur in this same cluster (**Figures 3B,C**). Of patients self-reporting fever, almost all experienced another symptom, with only 2 individuals reporting fever alone (one after d3+BA.1, and one after d2+Delta).

While the majority of participants were not febrile (77% or 62% for d3+BA.1 or BA.2), NHS guidance also recommends self-isolation if an individual feels too unwell to carry out their routine activities. On the assumption that those reporting moderate severity symptoms (grades II or III) would not be able to attend work under the April 2022 guidelines(17) and therefore would self-isolate, 51% of our cohort with active infection (3d+BA.1 [60%] or 3d+BA.2 [41%]) would still not meet self-isolation criteria for either for fever or severity, and thus would enter social circulation whilst likely infectious.

To test if symptoms were associated with viral replication, we examined infection dynamics in more detail. Participants who reported acute infection provided serial nasopharyngeal swabs for RT-qPCR analysis of SARS-CoV-2 RNA. We profiled the kinetics of each infection using the Ct value, inversely representative of levels of replicating virus (20). Across all cohorts, the median Ct values remained at levels considered to be infectious for 7-10 days, irrespective of symptom severity and including asymptomatic participants (**Figure 4A**). The lowest Ct values (corresponding to estimated peak viral load,(20)) were observed between 2-5 days after symptom onset, with similar Ct trajectories observed across all VOCs tested. We did not observe a significant difference in the lowest Ct value, in those who experienced BA.2 infection (median minimum Ct 17.5) following 3 doses as compared to BA.1 (median minimum Ct 19.2, $p=0.088$) (**Figure 4B**).

Notably, there was also no significant difference in lowest Ct values in those who met the updated NHS criteria for isolation and those who did not. Amongst symptomatic individuals, the presence of fever did not significantly affect the lowest Ct value for either BA.1 or BA.2 infections: median minimum Ct febrile vs. afebrile BA.1 (16.2 vs 19.2, $p=0.302$) and BA.2 (15.8

vs 18.0, $p=0.076$) (**Figure 4C and D**). Furthermore, the self-reported severity grade was not associated with differences in lowest Ct measurements for either BA.1 (lowest Ct grade I vs grades II-III = 20.9 vs 16.5, $p=0.131$) or BA.2 (lowest Cts grade I vs grades II-III = 17.6 vs 17.5, $p=0.878$) (**Figure 4E**). We did detect a trend towards lower Ct and increasing time since last vaccination dose that was significant for BA.1 infection after 3 doses ($R^2 = 0.49$ $p=0.0002$), but this did not reach statistical significance for BA.2 ($R^2=0.097$ $p=0.053$) (**Figure 4F**).

Discussion

Taken together, our data suggest that changes in both the properties of VOCs and changing population immunity has driven a rapid change in observed symptoms of COVID-19, and that only a minority of infected adults would now be advised to self-isolate following the latest symptom-based UK guidance, despite having equally high viral loads in the nasopharynx across VOCs that persisted beyond recommended isolation periods.

Fundamentally, our data reflect a significant shift in the constellation of symptoms that characterise COVID-19 cases caused by both Omicron BA.1 and BA.2 in vaccinated individuals, away from the original cardinal NHS symptoms of fever/cough/anosmia derived from COVID-19 cases in 2020. These results are consistent with self-reported symptom data during the BA.1 wave from the ZOE study, a large smartphone app-based community study in the UK and are supportive of the expansion of cardinal symptoms by the NHS in its COVID-19 guidance issued in April 2022 (13, 15).

Despite analyses of hospitalisation and mortality data indicating that Omicron caused less-severe clinical disease (7, 8, 10), our data suggests that COVID-19 continues to cause a significant symptom burden in non-hospitalised adults with COVID-19, with attendant impacts on healthcare resources, and incidence of post-COVID syndrome (PCS) (11, 12). This continued burden is well-illustrated by the shift in the numbers of asymptomatic cases we

detected: for Delta infection following three vaccine doses, all cases were asymptomatic, contrasting with Omicron sub-variants who were more likely to be symptomatic, despite a similar 3-month interval since vaccination and nearly-identical viral kinetics across VOCs. A possible interpretation on the changing numbers of asymptomatic infections is that the immediate boosting effect of third vaccine doses minimises symptomatic disease, but this protection is short-lived and therefore more individuals were vulnerable to symptomatic disease at the longer post-dose intervals when BA.2 emerged (21, 22)(13). Indeed, our data on changing rates of asymptomatic infections, associated with time since vaccination and increasing viral loads, not captured by previous studies suggests that COVID-19 caused by future VOCs may have greater impact than the current circulating Omicron sub-variants (13, 14).

It is not fully clear from our data to what extent vaccination suppresses viral replication and transmission. We observed almost identical viral kinetics across VOCs, irrespective of vaccination status, which corresponded closely with those found during both controlled human challenge models in unvaccinated individuals and asymptomatic household transmission in South Africa (14, 20), suggesting that immunity induced by first-generation vaccines encoding an ancestral Spike might have minimal impact on viral replication in the nasopharynx. However, we also observed a trend towards higher peak viral loads after longer time since vaccination that reached significance in BA.1 infections, mirroring waning neutralising antibodies in vaccinated cohorts (23). Coupled with the similarity in symptom profiles between those infected with BA.1 and BA.2, waning of neutralising antibodies induced by vaccination may be marginally implicated in viral clearance, in parallel with increasing risk of hospitalisation with earlier VOC (23-25). Such results would also be consistent with reduced transmission inferred from household attack rates in vaccinated cohorts (26).

While our study does not examine transmission directly, it is notable that nearly participants had low Ct values corresponding with high viral loads in the nasopharynx that tended to remain

<25 beyond the isolation period recommended by many countries, including the UK and US (1, 17). The Ct values we measured are all consistent with Omicron in the general population (27), and are well within the range in which infectious virus could be detected during human challenge with SARS-CoV-2 (20), in prospectively sampled cohorts (28). The heterogeneity in lowest value and longitudinal Ct kinetics in our cohort are also very similar to other cohorts (29, 30). It is therefore likely that many participants in our study were highly infectious, potentially beyond current isolation periods. Isolation guidance for each emerging VOC should therefore be supported by both symptom data and mathematical models of transmission, based on updated transmission and viral kinetic data to reduce onwards transmission of new VOC (31).

Updated isolation guidance would also need to incorporate factors beyond those addressed in this study, notably data from younger & older age groups, from those at increased risk of severe COVID-19, and from the substantial minority who remain unvaccinated (20% of the English population) or have yet to take up a third 'booster' dose (28% of vaccinated adults in England) (9). Additionally, while we were able to obtain detailed prospective clinical and PCR data from our cohort across three waves of infection, we were not able to compare these data with earlier waves (i.e. Alpha/B.1.1.7, EU1/B.1.177, and D614G/B.1) as these preceded our study and period of enhanced infection surveillance. While we were unable to control for differences in clinical baseline demographics between infection groups, Legacy participants are representative of working age adults in London (4).

The viral load kinetics we observed were remarkably consistent and closely mirrored supervised testing in the SARS-CoV-2 human challenge study (20) (suggesting high quality samples were obtained at serial time points across participants), however serial PCR testing was not supervised by a clinician. Therefore, while participants were given clear instructions on testing and had been compliant with asymptomatic screening for excess of 12 months prior to the start of this study, sampling variability might limit the interpretation on Ct values and associated estimates of infectivity. Similarly, while symptom profiles and severity were self-

reported during infection, all diaries were checked for accuracy with the participant by a study clinician within 21 days of reported symptom onset to minimise recall bias.

It is also important to emphasise that given the observational nature of our study, the sequential spread of Omicron BA.1 and BA.2 in the United Kingdom, and the rapid expansion of third-dose vaccination in December 2021, it was not possible to determine whether differences we observed between Delta and the BA.1 and BA.2 VOCs were attributable to intrinsic differences between these variants, or waning of immune protection afforded by vaccination. The reported shift in COVID-19 symptoms between Delta and Omicron sub-variants may be driven by intrinsic differences in the biology of the virus itself, leading to modified host responses; mutations in the Spike protein of SARS-CoV-2 VOCs may directly impact on symptom profiles through changes in viral tropism (2, 3, 32, 33). However, detailed data on differences in the host response to different VOC in vaccinated, non-hospitalised adults are currently lacking, but are likely to involve an interplay between localised mucosal innate and early T-cell interferon-mediated systemic responses (2, 34, 35). Further studies to determine the mechanisms by which different and emerging VOCs affect the host response are urgently required, and will be a necessary counterpart to clinical studies in the assessment of future VOCs.

In conclusion, we report on the largest cohort study to compare both symptom profiles and viral kinetics in well-characterised healthy adults across recent SARS-CoV-2 VOCs. Our data show that symptoms experienced by vaccinated adults may continue to change with new SARS-CoV-2 VOCs. Guidance on self-isolation and testing requires regular evaluation from prospective clinical studies as new VOCs emerge, and notably, neither illness severity nor presence of fever is a useful proxy for testing when considering the need for self-isolation. Updated advice should continue to emphasise the ongoing risk of transmission from individuals with no or mild symptoms whilst infected with Omicron to vulnerable populations,

and the possibility for characteristic symptoms to change in the future were a new VOC to emerge.

Funding

This work was supported by UCLH/UCL who received a proportion of funding from the National Institute for Health Research (NIHR) University College London Hospitals Department of Health's NIHR Biomedical Research Centre (BRC). EW, VL and BW are supported by the Centre's funding scheme. This work was supported jointly by the BRC and core funding from the Francis Crick Institute, which receives its funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust. This research was funded in whole, or in part, by the Wellcome Trust [FC011104, FC011233, FC001030, FC001159, FC001827, FC001078, FC001099, FC001169, 206250/Z/17/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. DLVB is additionally supported by the Genotype-to-Phenotype National Virology Consortium (G2P-UK) via UK Research and Innovation and the UK Medical Research Council, and TWR and AJK are additionally supported by the Wellcome Trust. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data and the final responsibility to submit for publication.

Declaration of interests

CSw reports interests unrelated to this Correspondence: grants from BMS, Ono-Pharmaceuticals, Boehringer-Ingelheim, Roche-Ventana, Pfizer and Archer Dx, unrelated to this Correspondence; personal fees from Genentech, Sarah Canon Research Institute, Medicxi, Bicycle Therapeutics, GRAIL, Amgen, AstraZeneca, BMS, Illumina, GlaxoSmithKline, MSD, and Roche-Ventana, unrelated to this Correspondence; and stock options from Apogen Biotech, Epic Biosciences, GRAIL, and Achilles Therapeutics, unrelated to this Correspondence. DLVB reports grants from AstraZeneca unrelated to this Correspondence. All other authors declare no competing interests.

Acknowledgements

The authors would like to thank all the study participants, the staff of the NIHR Clinical Research Facility at UCLH including Kirsty Adams and Marivic Ricamara. We would like to thank Jules Marczak, Gita Mistry, and the staff of the Scientific Technology Platforms (STPs) and COVID-19 testing pipeline at the Francis Crick Institute.

Table 1: Demographic details of Legacy study participants with post-vaccine SARS-CoV-2 infection

Characteristic	Delta 2, N = 61¹	Delta 3, N = 6¹	Omicron BA.1 2, N = = 20¹	Omicron BA.1 3, N = 116¹	Omicron BA.2 3, N = 104¹
Dose 2					
AZD1222	30 (49%)	0 (0%)	8 (40%)	25 (22%)	29 (28%)
BNT162b2	30 (49%)	6 (100%)	9 (45%)	87 (75%)	68 (65%)
mRNA1272	1 (1.6%)	0 (0%)	3 (15%)	4 (3.4%)	6 (5.8%)
others	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1.0%)
Dose 3					
AZD1222	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
BNT162b2	37 (73%)	6 (100%)	9 (100%)	106 (91%)	99 (95%)
mRNA1272	14 (27%)	0 (0%)	0 (0%)	9 (7.8%)	5 (4.8%)
others	0 (0%)	0 (0%)	0 (0%)	1 (0.9%)	0 (0%)
Unknown	10	0	11	0	0
Site					
Crick (non-NHS)	47 (77%)	5 (83%)	20 (100%)	81 (70%)	90 (87%)
NHS	14 (22%)	1 (17%)	0 (0%)	35 (30%)	14 (13%)
Sex					
Female	38 (62%)	3 (50%)	12 (60%)	81 (70%)	73 (70%)
Male	23 (38%)	3 (50%)	8 (40%)	35 (30%)	31 (30%)
Median age (years) [IQR]	39 [29-48]	40 [33-49]	32 [29-38]	42 [34-50]	37 [30-46]
VOC identified by viral sequencing, SGTF+date, or date					
wildtype	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
D614G	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Alpha	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Beta	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Delta	61 (100%)	6 (100%)	0 (0%)	0 (0%)	0 (0%)
Omicron BA.1	0 (0%)	0 (0%)	20 (100%)	116 (100%)	0 (0%)
Omicron BA.2	0 (0%)	0 (0%)	0 (0%)	0 (0%)	104 (100%)
Episode number					
1	61 (100%)	6 (100%)	18 (90%)	111 (96%)	90 (87%)
2	0 (0%)	0 (0%)	2 (10%)	5 (4.3%)	14 (13%)
Joined study before infection episode?					
No	24 (39%)	3 (50%)	12 (60%)	45 (39%)	31 (30%)
Yes	37 (61%)	3 (50%)	8 (40%)	71 (61%)	73 (70%)
Median days since dose prior to infection [IQR]	156 [110-190]	36 [25-56]	212 [170-261]	78 [44-100]	109 [92-157]
Self-reported symptom severity					
grade I	23 (38%)	0 (0%)	11 (61%)	40 (35%)	35 (35%)
grade II	24 (39%)	0 (0%)	3 (17%)	40 (35%)	50 (51%)
grade III	0 (0%)	0 (0%)	0 (0%)	2 (1.8%)	1 (1.0%)
asymptomatic	14 (23%)	5 (100%)	4 (22%)	32 (28%)	13 (13%)
Unknown	0	1	2	2	5
Self-reported duration of symptoms	10 [7-20]	8 [4-14]	10 [7-14]	9 [6-12]	10 [7-14]
¹ n (%); Median [25%-75%]					

Figure Legends

Figure 1: *Flow diagram of post-vaccine infections in the Legacy study*

Figure 2: *Symptoms of COVID-19 are an interaction between prevailing variants and vaccinations.*

Time in days after vaccine dose before the start of an infection episode is shown for infections 14d or more after doses 2 or 3 by each VOC. The number of infection episodes in each group are shown with demographics in Table 1. **(B)** The proportion of participants reporting no (asymptomatic), mild, moderate, or severe symptoms during their infection episode. **(C)** The duration of each infection episode in days is shown stratified by the VOC and number of doses received prior to infection. **(D)** The percentages of individuals reported the indicated symptoms are shown as a heatmap. For Delta after 3 doses, all individuals were asymptomatic. Each symptom could be present, asymptomatic (not present), or not reported (no study questionnaire filed). The percentage of individuals reporting that symptom is shown in each tile, the tiles shaded to reflect that percentage, and the denominator used is all infection episodes of the corresponding VOC and number of doses. **(E)** Bar plot showing the proportion of symptomatic individuals who reported any of NHS' cardinal symptoms of cough, fever or loss of smell (in dark blue), individuals whose symptoms did not include a cardinal symptom (in light blue), and individuals who were asymptomatic (in grey). **(F)** The proportion of symptomatic individuals with at least one of the cardinal NHS symptoms (in dark blue) or alternative combinations of symptoms (in light blue) for each VOC and infections after the indicated number of doses. Grey shading indicates individuals who did not meet that bar's symptom definition.

Figure 3: *Hierarchical clustering of symptom patterns in infection episodes occurring after dose 2 in the Legacy study*

All symptomatic episodes from the Legacy cohort clustered by individual (columns) and

symptoms (rows) using Jaccard distances. The presence of a symptom is indicated by rose shading and the absence of a symptom by grey shading. Above each individual episode (each column) the colour bar indicates the severity, assigned VOC of that infection episode, and the number of doses of vaccine received before that infection. An individual may be present >1 if they experienced more than one infection episodes. Symptomatic episodes depicted across all VOCs in **(A)**, only for Omicron-BA.1 episodes **(B)**, or BA.2 episodes **(C)**. In (B) and (C), episodes are grouped by their severity, whereas symptoms are clustered. Asymptomatic infection episodes are not shown.

Figure 4: Peak viral load from symptomatic infection episodes in triple-vaccinated participants, compared to days since vaccination.

(A) Viral load (Ct) trajectories (day 0 = symptom onset), plotted separately for each variant and stratified by the number of preceding vaccinations. Smoothed spline fits are shown. **(B)** Peak viral load on days 1-4 following symptom onset from Delta, Omicron BA.1 and BA.2 infection episodes by vaccine dose number. **(C)** Viral load (Ct) trajectories in for symptomatic BA.1 or BA.2 infections with febrile and afebrile infection episodes in dark or light blue respectively. Smoothed spline fits are shown. **(D)** Peak viral load on days 1-4 in participants with either BA.1 or BA.2 reported by the presence or absence of fever, or **(E)** symptom severity grade. **(F)** Peak Ct value across all VOCs plotted against the time in days since last vaccine dose after either two or three vaccine doses. Lines from linear regression are shown, with Spearman's R2 and P values shown.




Figure 1: Flow diagram of post-vaccine infections in the Legacy study




Figure 2. Symptoms of COVID-19 are an interaction between prevailing variants and vaccinations. (A) Time in days after vaccine dose before the start of an infection episode is shown for infections 14d or more after doses 2 or 3 by each VOC. The number of infection episodes in each group are shown with demographics in Table 1. **(B)** The proportion of participants reporting no (asymptomatic), mild, moderate, or severe symptoms during their infection episode. **(C)** The duration of each infection episode in days is shown stratified by the VOC and number of doses received prior to infection. **(D)** The percentages of individuals reported the indicated symptoms are shown as a heatmap. For Delta after 3 doses, all individuals were asymptomatic. Each symptom could be present, asymptomatic (not present), or not reported (no study questionnaire filed). The percentage of individuals reporting that symptom is shown in each tile, the tiles shaded to reflect that percentage, and the denominator used is all infection episodes of the corresponding VOC and number of doses. **(E)** Bar plot showing the proportion of symptomatic individuals who reported any of NHS' cardinal symptoms of cough, fever or loss of smell (in dark blue), individuals whose symptoms did not include a cardinal symptom (in light blue), and individuals who were asymptomatic (in grey). **(F)** The proportion of symptomatic individuals with at least one of the cardinal NHS symptoms (in dark blue) or alternative combinations of symptoms (in light blue) for each VOC and infections after the indicated number of doses. Grey shading indicates individuals who did not meet that bar's symptom definition.




Figure 3. Hierarchical clustering of symptom patterns in infection episodes occurring after dose 2 in the Legacy study. All symptomatic episodes from the Legacy cohort clustered by individual (columns) and symptoms (rows) using Jaccard distances. The presence of a symptom is indicated by rose shading and the absence of a symptom by grey shading. Above each individual episode (each column) the colour bar indicates the severity, assigned VOC of that infection episode, and the number of doses of vaccine received before that infection. An individual may be present >1 if they experienced more than one infection episodes. Symptomatic episodes depicted across all VOCs in (A), only for Omicron-BA.1 episodes (B), or BA.2 episodes (C). In (B) and (C), episodes are grouped by their severity, whereas symptoms are clustered. Asymptomatic infection episodes are not shown.




Figure 4. Peak viral load from symptomatic infection episodes in triple-vaccinated participants, compared to days since vaccination. (A) Viral load (Ct) trajectories (day 0 = symptom onset), plotted separately for each variant and stratified by the number of preceding vaccinations. Smoothed spline fits are shown. **(B)** Peak viral load on days 1-4 following symptom onset from Delta, Omicron BA.1 and BA.2 infection episodes by vaccine dose number. **(C)** Viral load (Ct) trajectories in for symptomatic BA.1 or BA.2 infections with febrile and afebrile infection episodes in dark or light blue respectively. Smoothed spline fits are shown. **(D)** Peak viral load on days 1-4 in participants with either BA.1 or BA.2 reported by the presence or absence of fever, or **(E)** symptom severity grade. **(F)** Peak Ct value across all VOCs plotted against the time in days since last vaccine dose after either two or three vaccine doses. Lines from linear regression are shown, with Spearman's R^2 and P values shown.

References

1. Prevention CfDCa. Ending Isolation and Precautions for People with COVID-19: Interim Guidance: CDC; 2022 [updated 14/1/2022. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>.
2. Thorne LG, Bouhaddou M, Reuschl AK, Zuliani-Alvarez L, Polacco B, Pelin A, et al. Evolution of enhanced innate immune evasion by SARS-CoV-2. *Nature*. 2022;602(7897):487-95.
3. Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. *bioRxiv*. 2022:2021.12.31.474653.
4. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *Lancet*. 2021;397(10292):2331-3.
5. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. *Lancet*. 2021;398(10296):207-9.
6. Wu M, Wall EC, Carr EJ, Harvey R, Townsley H, Mears HV, et al. Three-dose vaccination elicits neutralising antibodies against omicron. *Lancet*. 2022;399(10326):715-7.
7. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med*. 2022;386(16):1532-46.
8. Bager P, Wohlfahrt J, Bhatt S, Stegger M, Legarth R, Moller CH, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. *Lancet Infect Dis*. 2022;22(7):967-76.
9. Government U. Coronavirus dashboard 2022 [cited 2022 29/6/2022]. Available from: <https://coronavirus.data.gov.uk/>.

10. Nunes MC, Mbotwe-Sibanda S, Baillie VL, Kwatra G, Aguas R, Madhi SA, et al. SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers. *Vaccines (Basel)*. 2022;10(3).
11. Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. *BMJ*. 2022;377:e069676.
12. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. *Lancet*. 2022;399(10343):2263-4.
13. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. *Lancet*. 2022;399(10335):1618-24.
14. Cohen C, Kleynhans J, von Gottberg A, McMorrow ML, Wolter N, Bhiman JN, et al. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21. *Lancet Infect Dis*. 2022;22(6):821-34.
15. NHS. COVID-19 when to self-isolate and what to do 2022 [Available from: <https://www.nhs.uk/conditions/coronavirus-covid-19/self-isolation-and-treatment/when-to-self-isolate-and-what-to-do/>].
16. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis*. 2020;20(8):e192-e7.
17. Government U. Guidance for people with symptoms of a respiratory viral infection including COVID-19: gov.uk; 2022 [Available from: <https://www.gov.uk/guidance/people-with-symptoms-of-a-respiratory-infection-including-covid-19#higher-risk>].
18. Aitken J, Ambrose K, Barrell S, Beale R, Bineva-Todd G, Biswas D, et al. Scalable and robust SARS-CoV-2 testing in an academic center. *Nat Biotechnol*. 2020;38(8):927-31.
19. R. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2022.

20. Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. *Nat Med*. 2022;28(5):1031-41.
21. Garrett N, Tapley A, Andriesen J, Seocharan I, Fisher LH, Bunts L, et al. High Asymptomatic Carriage with the Omicron Variant in South Africa. *Clin Infect Dis*. 2022.
22. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. *N Engl J Med*. 2022;386(4):340-50.
23. Katikireddi SV, Cerqueira-Silva T, Vasileiou E, Robertson C, Amele S, Pan J, et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. *Lancet*. 2022;399(10319):25-35.
24. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet*. 2021;397(10283):1459-69.
25. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet*. 2022;399(10328):924-44.
26. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. *medRxiv*. 2022:2022.01.28.22270044.
27. Yapp R R, J. Coronavirus (COVID-19) Infection Survey, UK: 27 May 2022: ONS; 2022 [31/5/2022]. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/latest#viral-load-and-variants-of-covid-19>.

28. Pekosz A, Parvu V, Li M, Andrews JC, Manabe YC, Kodsi S, et al. Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture. *Clin Infect Dis*. 2021;73(9):e2861-e6.
29. Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. *Nat Microbiol*. 2022;7(5):640-52.
30. Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, et al. Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant. *medRxiv*. 2022:2022.01.13.22269257.
31. Hellewell J, Russell TW, Investigators S, Field Study T, Crick C-C, group CC-w, et al. Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections. *BMC Med*. 2021;19(1):106.
32. Mesner D, Reuschl A-K, Whelan MVX, Bronzovich T, Haider T, Thorne LG, et al. SARS-CoV-2 Spike evolution influences GBP and IFITM sensitivity. *bioRxiv*. 2022:2022.03.07.481785.
33. Kanakan A, Mehta P, Devi P, Saifi S, Swaminathan A, Maurya R, et al. Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations? *Front Microbiol*. 2022;13:763169.
34. Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. *Nature*. 2022;601(7891):110-7.
35. Chandran A, Rosenheim J, Nageswaran G, Swadling L, Pollara G, Gupta RK, et al. Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections. *Cell Rep Med*. 2022;3(3):100557.

